Alseroxylon
Rautensin, Rauwiloid (alseroxylon) is a small molecule pharmaceutical. Alseroxylon was first approved as Rauwiloid on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
170 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gout | D006073 | EFO_0004274 | M10 | 2 | 11 | 12 | 7 | 4 | 36 |
| Hyperuricemia | D033461 | 1 | 7 | 4 | 4 | 4 | 20 | ||
| Chronic renal insufficiency | D051436 | N18 | 3 | 3 | — | 1 | 2 | 9 | |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 5 | 1 | 3 | — | 8 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 4 | 1 | 2 | 1 | — | 7 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 3 | 2 | 1 | — | 5 |
| Kidney calculi | D007669 | EFO_0004253 | N20.0 | — | 1 | — | 2 | — | 3 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | 1 | 1 | 3 | |
| Mania | D000087122 | F30 | — | — | 1 | 2 | — | 3 | |
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | 3 | — | 3 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 2 | 4 | 2 | — | 1 | 8 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | — | 2 | 2 | — | 1 | 5 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | 2 | — | — | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | 2 | — | — | 3 |
| Prehypertension | D058246 | — | 2 | 1 | — | — | 2 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | 1 | 2 |
| Neoplasms | D009369 | C80 | — | 1 | 1 | — | — | 2 | |
| Tumor lysis syndrome | D015275 | E88.3 | — | — | 2 | — | — | 2 | |
| Coronary artery disease | D003324 | I25.1 | — | — | 1 | — | 1 | 2 | |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | 1 | 1 | — | — | 2 |
Show 17 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | 2 | 6 | — | — | — | 8 | |
| Myelodysplastic syndromes | D009190 | D46 | 2 | 3 | — | — | 1 | 6 | |
| Lymphoma | D008223 | C85.9 | 2 | 3 | — | — | — | 5 | |
| Multiple myeloma | D009101 | C90.0 | 1 | 3 | — | — | — | 4 | |
| Myeloid leukemia acute | D015470 | C92.0 | — | 3 | — | — | 1 | 4 | |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | — | — | 2 | 3 |
| Plasma cell neoplasms | D054219 | 2 | 1 | — | — | — | 3 | ||
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 2 | — | — | — | 2 | |
| Burkitt lymphoma | D002051 | C83.7 | — | 2 | — | — | — | 2 | |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | 2 | — | — | — | 2 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 6 | — | — | — | — | 6 | ||
| Heart disease risk factors | D000082742 | 3 | — | — | — | — | 3 | ||
| Vasoconstriction | D014661 | 2 | — | — | — | — | 2 | ||
| Myeloproliferative disorders | D009196 | D47.1 | 1 | — | — | — | — | 1 | |
| Graft vs host disease | D006086 | D89.81 | 1 | — | — | — | — | 1 | |
| Vasodilation | D014664 | 1 | — | — | — | — | 1 | ||
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | — | — | — | — | 1 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cutaneous leishmaniasis | D016773 | B55.1 | — | — | — | — | 2 | 2 | |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
| Endoscopic retrograde cholangiopancreatography | D002760 | — | — | — | — | 1 | 1 | ||
| Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | — | — | 1 | 1 | |
| Fetal growth retardation | D005317 | EFO_0000495 | — | — | — | — | 1 | 1 | |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | — | 1 | 1 |
| Chronic kidney disease-mineral and bone disorder | D012080 | EFO_1001152 | N25.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ALSEROXYLON |
| INN | — |
| Description | Alseroxylon (Rautensin, Rauwiloid) is a norepinephrine reuptake inhibitor that has been investigated in the treatment of hypertension and angina pectoris and as a sedative in psychoses. It was at one time approved for use in the United States, but has since been discontinued.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 8001-95-4 |
| RxCUI | 599 |
| ChEMBL ID | CHEMBL1201454 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00386 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 62 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18,299 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more